Danish | Pakistani | ||||
---|---|---|---|---|---|
Placebo (n = 35) | Fortified (n = 31) | Placebo (n = 37) | Fortified (n = 33) | P2 | |
OC (μg/L) | |||||
Baseline | 23.9 (9.6)d | 25.2 (8.7)bc | 19.6 (8.4)c | 18.2 (5.6)bd | 0.001 |
Endpoint | 22.3 (9.0) | 22.7 (6.8)b | 19.5 (8.9) | 17.4 (5.0)b | 0.03 |
Change | −1.2 (4.2) | −2.3 (4.6) | −0.20 (4.0) | −0.5 (2.9) | 0.19 |
CTX (ng/mL) | |||||
Baseline | 0.25 (0.14) | 0.30 (0.15) | 0.27 (0.19) | 0.21 (0.1) | 0.13 |
Endpoint | 0.23 (0.14) | 0.26 (0.12) | 0.24 (0.16) | 0.19 (0.1) | 0.20 |
Change | −0.006 (0.1) | − 0.05 (0.1) | − 0.03 (0.1) | − 0.02 (0.1) | 0.38 |
BALP (μg/L) | |||||
Baseline | 15.5 (7.0) | 16.6 (5.2) | 15.9 (5.2) | 16.9 (7.9) | 0.79 |
Endpoint | 13.4 (5.4) | 14.0 (4.4) | 14.6 (4.9) | 14.6 (6.0) | 0.74 |
Change | −1.5 (3.5) | −1.5 (3.6) | − 1.4 (2.1) | − 1.8 (4.5) | 0.97 |
P1NP (μg/L) | |||||
Baseline | 50.7 (25.2) | 54.6 (19.6) | 46.6 (19.6) | 48.1 (17.2) | 0.42 |
Endpoint | 46.4 (23.8) | 51.1 (16.8) | 48.5 (21.0) | 45.7 (14.7) | 0.72 |
Change | −2.0 (7.9) | −2.6 (11.0) | 1.7 (10.3) | −1.7 (10.4) | 0.31 |